Vicapsys Life Sciences, Inc.
Close on Oct 19, 2026
- Market cap
- $13.73M
- P/E (TTM)
- –
- Dividend yield
- –
About Vicapsys Life Sciences
Pharmaceutical Preparations, SIC 2834
Vicapsys Life Sciences, Inc. is a preclinical biotechnology company focused on developing and commercializing therapeutic technologies that create zones of immunoprotection. Utilizing proprietary derivatives of the chemokine CXCL12 licensed from Massachusetts General Hospital, the company designs encapsulated product candidates to shield transplanted cells, tissues, organs, and medical devices from immune destruction and fibrotic encapsulation. Its development pipeline includes VICAPSYN, an encapsulated human islet cell cluster designed for transplantation therapies to treat patients suffering from Type 1 diabetes, and VYBRIN, an anti-fibrotic product candidate being explored to prevent post-surgical abdominal adhesions, coat implantable medical devices, and promote diabetic ulcer wound healing.
The company operates at a preclinical stage without commercial products or sales, conducting its research, development, and testing through academic and clinical partnerships, as well as third-party contract manufacturers. Vicapsys Life Sciences maintains its principal executive offices in Suwanee, Georgia.
Summary of the business section of Vicapsys Life Sciences's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Vicapsys Life Sciences, Inc.
- Founded
- 1997
- Headquarters
- Cumming, GA
- Address
- 1735 Buford Highway, Ste. 215-113 30041
- Phone
- (470) 514-4013
- Employees
- 2, Dec 31, 2023
- Industry
- Pharmaceutical Preparations
- Incorporated in
- Florida
- Fiscal year ends
- December 31
- Auditor
- Assurance Dimensions, Coral Springs, Florida
Stock & identifiers
- Ticker
- VICP
- Exchange
- OTC
- Shares outstanding
- 32M, Nov 18, 2024
- Public float
- $4.66M, Jun 30, 2024
- Filer category
- Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
- Stock splits
- 1-for-100 reverse, Nov 2, 2017; 1-for-35 reverse, Feb 22, 2008
- SEC CIK
- 1468639
- EIN
- 62-1153426
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
No recent ownership filings by officers or directors
Vicapsys Life Sciences's leadership is listed in its proxy statement (Form DEF 14A).
Employees
Headcount reported in annual reports
“As of December 31, 2023, we have two employees.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Mar 27, 2025 | Deregistration | Termination of SEC registration (Form 15) |
| May 18, 2023 | Auditor change | Change in certifying accountant (8-K Item 4.01) |
| May 17, 2023 | Auditor change | Change in certifying accountant (8-K Item 4.01) |
| Mar 31, 2023 | Late filing | Notification of late filing |
| Nov 14, 2022 | Late filing | Notification of late filing |
| Aug 15, 2022 | Late filing | Notification of late filing |
| Nov 7, 2016 | Deregistration | Termination of SEC registration (Form 15) |
| Nov 7, 2016 | Name change | Name changed from SSGI, INC. to Vicapsys Life Sciences, Inc. |
| Aug 16, 2010 | Late filing | Notification of late filing |
| Jul 29, 2010 | Acquisition / sale | Completion of acquisition or disposition of assets (8-K Item 2.01) |
| May 18, 2010 | Acquisition / sale | Completion of acquisition or disposition of assets (8-K Item 2.01) |
| May 17, 2010 | Late filing | Notification of late filing |
| Apr 1, 2010 | Late filing | Notification of late filing |